Works matching AU Bolli, Geremia B.
Results: 106
Comparable efficacy with similarly low risk of hypoglycaemia in patient‐ vs physician‐managed basal insulin initiation and titration in insulin‐naïve type 2 diabetic subjects: The Italian Titration Approach Study.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2020, v. 36, n. 6, p. 1, doi. 10.1002/dmrr.3304
- By:
- Publication type:
- Article
Comparable efficacy with similarly low risk of hypoglycaemia in patient- vs physician-managed basal insulin initiation and titration in insulin-naïve type 2 diabetic subjects: The Italian Titration Approach Study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Insulin- and Exercise-Stimulated Skeletal Muscle Blood Flow and Glucose Uptake in Obese Men.
- Published in:
- Obesity (19307381), 2003, v. 11, n. 2, p. 257, doi. 10.1038/oby.2003.39
- By:
- Publication type:
- Article
Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus.
- Published in:
- Archives of Physiology & Biochemistry, 2008, v. 114, n. 1, p. 3, doi. 10.1080/13813450801900777
- By:
- Publication type:
- Article
Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL<sup>-1</sup> and Insulin Degludec 100 units · mL<sup>-1</sup> in Type 1 Diabetes.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes.
- Published in:
- 2019
- By:
- Publication type:
- journal article
John E. Gerich: Father of Modern Physiology of Glucose Homeostasis, Counterregulation to Hypoglycemia, and Mechanistic Treatment of Diabetes.
- Published in:
- 2018
- By:
- Publication type:
- journal article
More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
- Published in:
- 2015
- By:
- Publication type:
- journal article
How to Accurately Establish Pharmacokinetics/Pharmacodynamics of Long-Acting Insulins in Humans: Relevance to Biosimilar Insulins.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin.
- Published in:
- Diabetes Care, 2015, v. 38, n. 7, p. e96, doi. 10.2337/dc14-2662
- By:
- Publication type:
- Article
New Long-Acting Insulin Analogs: From Clamp Studies to Clinical Practice.
- Published in:
- Diabetes Care, 2015, v. 38, n. 4, p. 541, doi. 10.2337/dc14-2314
- By:
- Publication type:
- Article
Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes.
- Published in:
- Diabetes Care, 2015, v. 38, n. 3, p. 503, doi. 10.2337/dc14-0649
- By:
- Publication type:
- Article
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1).
- Published in:
- Diabetes Care, 2014, v. 37, n. 10, p. 2755, doi. 10.2337/dc14-0991
- By:
- Publication type:
- Article
Thirty Years of Research on the Dawn Phenomenon: Lessons to Optimize Blood Glucose Control in Diabetes.
- Published in:
- 2013
- By:
- Publication type:
- Opinion
The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.
- Published in:
- 2013
- By:
- Publication type:
- journal article
The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes.
- Published in:
- Diabetes Care, 2013, v. 36, n. 3, p. 498, doi. 10.2337/dc12-0709
- By:
- Publication type:
- Article
Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes.
- Published in:
- Diabetes Care, 2012, v. 35, n. 12, p. 2626, doi. 10.2337/dc12-0270
- By:
- Publication type:
- Article
Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes.
- Published in:
- Diabetes Care, 2012, v. 35, n. 12, p. 2647, doi. 10.2337/dc12-0271
- By:
- Publication type:
- Article
Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus.
- Published in:
- Diabetes Care, 2011, v. 34, n. 12, p. 2521, doi. 10.2337/dc11-1064
- By:
- Publication type:
- Article
Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects.
- Published in:
- Diabetes Care, 2011, v. 34, n. 6, p. 1312, doi. 10.2337/dc10-1911
- By:
- Publication type:
- Article
Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes.
- Published in:
- Diabetes Care, 2011, v. 34, p. S220, doi. 10.2337/dc11-s224
- By:
- Publication type:
- Article
Hypoglycemia, Diabetes, and Cardiovascular Events.
- Published in:
- Diabetes Care, 2010, v. 33, n. 6, p. 1389, doi. 10.2337/dc09-2082
- By:
- Publication type:
- Article
Hyperglycemia-Induced Platelet Activation in Type 2 Diabetes Is Resistant to Aspirin but Not to a Nitric Oxide-Donating Agent.
- Published in:
- Diabetes Care, 2010, v. 33, n. 6, p. 1262, doi. 10.2337/dc09-2013
- By:
- Publication type:
- Article
Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes.
- Published in:
- Diabetes Care, 2009, v. 32, n. 7, p. 1170, doi. 10.2337/dc08-1874
- By:
- Publication type:
- Article
Insulin: evolution of insulin formulations and their application in clinical practice over 100 years.
- Published in:
- Acta Diabetologica, 2022, v. 59, n. 9, p. 1129, doi. 10.1007/s00592-022-01938-4
- By:
- Publication type:
- Article
Short-Term Effects of the Long-Acting Insulin Analog Detemir and Human Insulin on Plasma Levels of Insulin-Like Growth Factor-I and Its Binding Proteins in Humans.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2009, v. 94, n. 8, p. 3017, doi. 10.1210/jc.2008-2838
- By:
- Publication type:
- Article
Autoantibody Recognition of COOH-Terminal Epitopes of GAD65 Marks the Risk for Insulin Requirement in Adult-Onset Diabetes Mellitus.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2000, v. 85, n. 1, p. 309, doi. 10.1210/jcem.85.1.6301
- By:
- Publication type:
- Article
Gender Differences in Basal Protein Kinetics in Young Adults.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 1998, v. 83, n. 12, p. 4363, doi. 10.1210/jcem.83.12.5330
- By:
- Publication type:
- Article
Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 2, p. 503, doi. 10.1111/dom.15336
- By:
- Publication type:
- Article
A comparison of the effectiveness and safety of insulin glargine 300 U/ml versus 100 U/ml in children and adolescents with newly diagnosed type 1 diabetes: A retrospective, observational, short‐term study.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 12, p. 2474, doi. 10.1111/dom.14839
- By:
- Publication type:
- Article
C‐peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 10, p. 1912, doi. 10.1111/dom.14785
- By:
- Publication type:
- Article
Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an ITAS post hoc analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 327, doi. 10.1111/dom.14560
- By:
- Publication type:
- Article
Insulin Centennial: Milestones influencing the development of insulin preparations since 1922.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, p. 27, doi. 10.1111/dom.14587
- By:
- Publication type:
- Article
Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 7, p. 1588, doi. 10.1111/dom.14372
- By:
- Publication type:
- Article
Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 1, p. 166, doi. 10.1111/dom.14212
- By:
- Publication type:
- Article
Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 10, p. 1880, doi. 10.1111/dom.14109
- By:
- Publication type:
- Article
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 9, p. 1664, doi. 10.1111/dom.14065
- By:
- Publication type:
- Article
Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 8, p. 1369, doi. 10.1111/dom.14043
- By:
- Publication type:
- Article
The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 5, p. 743, doi. 10.1111/dom.13963
- By:
- Publication type:
- Article
Fasting C‐peptide, a biomarker for hypoglycaemia risk in insulin‐naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 315, doi. 10.1111/dom.13897
- By:
- Publication type:
- Article
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 2, p. 321, doi. 10.1111/dom.13607
- By:
- Publication type:
- Article